Fink et al. showed that increased OCTN2 expression in GBM patients correlates with unfavorable outcomes, as demonstrated by decreased tumor cell viability upon OCTN2 silencing by siRNA-mediated activity (preclinical studies using a GBM mouse model). The gene discussed is SLC22A5; the disease is neoplasm.